Artivion (AORT) AI Stock Analysis

• Market Cap: $1.23B
• Dividend Yield: N/A
• Average Volume (3M): 452.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: 5.94%
• EPS Growth: -115.82%
• Country: US
• Employees: 1,600
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 42,702,785
• 10 Day Avg. Volume: 310,614
• 30 Day Avg. Volume: 452,051
• PEG Ratio: -0.96
• Price to Book (P/B): 1.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -30.58
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 0.52
• Enterprise Value/Gross Profit: 3.22
• Enterprise Value/Ebitda: 4.18
• 1Y Price Target: $32.50
• Price Target Upside: 15.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 68 Neutral
• Price Target: $32.00 ▲(13.27%Upside)

Artivion's overall score is driven by strong technical momentum and positive earnings call guidance, highlighting growth potential. However, profitability challenges and valuation concerns temper the score.

Positive Factors

Earnings

AORT's 1Q25 revenue and EBITDA beat consensus.

Growth Opportunities

The earlier-than-expected approval of the AMDS humanitarian-device-exemption is anticipated to positively contribute to 2025 top-line growth.

Market Expansion

Expectations for AORT to receive a premarket approval could expand its market coverage, representing a significant annual US market opportunity.

Negative Factors

Cybersecurity Incident

A cybersecurity incident impacted Q4 revenue by $4.5M due to inventory constraints, causing revenue to fall below expectations.

Financial Performance

The price target was lowered to $32 from $34, given the cybersecurity issue.

Short-term Challenges

The cyber incident is expected to continue affecting the company's performance in the immediate future, with management projecting lower 1Q25 revenues compared to previous estimates.

Artivion Business Overview & Revenue Model

Company Description

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

How the Company Makes Money

Artivion generates revenue through the sale of its medical devices and products to hospitals, healthcare facilities, and medical practitioners. The company's key revenue streams include the sale of surgical sealants, which are used to control bleeding during surgeries, and cryopreserved human tissues for cardiac and vascular reconstruction. Additionally, Artivion earns income through its mechanical heart valve products, which are crucial for patients requiring heart valve replacement. The company may also benefit from partnerships with healthcare providers and institutions that facilitate the adoption of its technologies in clinical settings. Sales and distribution agreements with global medical device distributors further expand its market reach, contributing to its financial performance.

Artivion Financial Statement Overview

Summary

Artivion demonstrates steady revenue growth with a solid gross profit margin. However, persistent net losses and negative net profit margins highlight profitability challenges. The balance sheet is stable with limited leverage, but high capital expenditures constrain free cash flow growth.

Income Statement

Artivion's income statement shows a modest revenue growth trend over the years, with TTM (Trailing-Twelve-Months) revenue at $390 million, representing a steady increase from previous years. However, the company has been consistently generating net losses, with a TTM net income of -$21.4 million. Gross profit margin remains strong at 62.9% TTM, but the negative net profit margin of -5.5% and declining EBIT margin to 4.5% TTM indicate profitability challenges.

Balance Sheet

The balance sheet reflects a stable equity base with stockholders' equity at $294 million TTM, but a high debt-to-equity ratio of 0.03 in TTM suggests manageable leverage. The equity ratio is a solid 37.2%, indicating a balanced capital structure. Despite these strengths, the negative net income affects return on equity, which remains negative.

Cash Flow

Artivion's cash flow statement indicates a mixed performance. While operating cash flow is positive at $13.6 million TTM, free cash flow growth is weak due to high capital expenditures, resulting in a modest free cash flow of $2.1 million TTM. The operating cash flow to net income ratio is positive, showing some operational efficiency despite net losses.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
390.08M	388.54M	354.00M	313.79M	298.84M	253.23M
	Gross Profit
249.41M	248.78M	229.18M	202.52M	197.51M	167.78M
	EBIT
15.71M	38.87M	5.74M	6.20M	8.12M	2.44M
	EBITDA
26.64M	38.87M	26.87M	25.30M	25.67M	27.50M
	Net Income Common Stockholders
-21.40M	-13.36M	-30.69M	-19.19M	-14.83M	-16.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
37.69M	53.46M	58.94M	39.35M	55.01M	61.41M
	Total Assets
791.16M	789.10M	792.40M	762.80M	793.05M	789.40M
	Total Debt
362.36M	362.26M	358.34M	356.83M	362.04M	317.37M
	Net Debt
324.67M	308.80M	299.40M	317.48M	307.03M	255.96M
	Total Liabilities
496.91M	512.90M	510.62M	478.47M	492.32M	460.69M
	Stockholders Equity
294.25M	276.20M	281.78M	284.33M	300.73M	328.71M
Cash Flow		Free Cash Flow
2.11M	11.05M	11.39M	-15.87M	-15.68M	5.04M
	Operating Cash Flow
10.78M	22.24M	18.82M	-5.15M	-2.58M	12.37M
	Investing Cash Flow
-28.21M	-28.19M	-502.00K	-10.71M	5.66M	-73.13M
	Financing Cash Flow
5.40M	2.20M	865.00K	-1.64M	-12.22M	93.61M

Artivion Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 28.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AORT, the sentiment is Neutral. The current price of 28.25 is below the 20-day moving average (MA) of 29.03, above the 50-day MA of 26.49, and above the 200-day MA of 27.15, indicating a neutral trend. The MACD of 0.50 indicates Positive momentum. The RSI at 49.54 is Neutral, neither overbought nor oversold. The STOCH value of 25.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AORT.

Artivion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AORT	68 Neutral	$1.23B	―	-7.25%	―	5.94%	-115.82%
KIDS	62 Neutral	$524.11M	―	-11.33%	―	31.28%	-81.86%
AXGN	56 Neutral	$457.26M	―	-7.22%	―	18.81%	67.41%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
TNDM	50 Neutral	$1.39B	―	-92.31%	―	27.65%	-28.22%
OFIX	49 Neutral	$437.26M	―	-27.82%	―	5.85%	-8.92%
BVS	47 Neutral	$551.19M	―	-19.79%	―	8.60%	-42.76%

Artivion Corporate Events

Artivion Completes Convertible Notes Exchange Agreement

On May 28, 2025, Artivion, Inc. announced the completion of transactions related to privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due 2025. These transactions involved exchanging approximately $99.54 million in principal amount of notes for 4,334,347 shares of common stock and a cash payment of $1.7 million for accrued interest. This move effectively retires the convertible notes, significantly reducing the company’s debt and enhancing its financial flexibility, as stated by CEO Pat Mackin.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Shareholders Approve Directors and Compensation

At the 2025 Annual Meeting of Stockholders on May 13, Artivion‘s shareholders elected all nominated directors and approved executive compensation packages. Additionally, they ratified Ernst & Young LLP as the independent auditor for 2025 and approved additional shares for the company’s equity incentive plan, indicating strong shareholder support for the company’s strategic direction.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Announces Convertible Notes Exchange Agreement

On May 14, 2025, Artivion, Inc. announced that it entered into privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due July 1, 2025. The agreements involve exchanging approximately $94.54 million in principal amount of these notes for shares of the company’s common stock, with the number of shares determined by the stock’s average trading price over a specified period. The transaction is expected to close around May 28, 2025, and will leave approximately $5.46 million of the notes outstanding. This strategic move is anticipated to impact Artivion’s financial structure and market positioning, potentially affecting stakeholders by altering the company’s debt and equity composition.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.